Metraipolis › archive › dc_7e45c4ddf59f

Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort — Europe PMC PMID:42434203

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42434203
DOI
10.1093/crocol/otag065
License (as archived)
solo-consultazione
Archived
2026-10-19T07:43:41.196Z
SHA-256 of the archived text
d0711a8f8833e36e2e02abefc04aa473130eb30678feecef436d7c1f037ead6e
Stable URL of this page
https://metraipolis.com/documento/dc_7e45c4ddf59f

How to cite

Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort — Europe PMC PMID:42434203 — Europe PMC (en), https://europepmc.org/article/MED/42434203 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7e45c4ddf59f (Metraipolis archive dc_7e45c4ddf59f, sha256 d0711a8f8833e36e2e02abefc04aa473130eb30678feecef436d7c1f037ead6e)
BibTeX
@misc{dc7e45c4ddf59f,
  title = {Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort — Europe PMC PMID:42434203},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42434203},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7e45c4ddf59f; sha256 d0711a8f8833e36e2e02abefc04aa473130eb30678feecef436d7c1f037ead6e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42434203. Agents can read the archived copy with the MCP tool read_document.